Skip to main content
Equibles
GUTS logo

GUTS

Fractyl Health, Inc.
$0.80 +0.04 (+4.99%) At close · Jul 14
Going-concern doubt — flagged May 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a result, substantial doubt exists about the Company's ability to continue as a going concern within twelve months from the issuance date of this Quarterly Report on Form 10-Q.”
View the 10-Q filed May 12, 2026
Market Cap
$144.37M
Shares
158,648,963

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.80 Open$0.76 Day$0.75–0.83 52W$0.38–2.45 Avg vol 30d1.4M Short int2.3M · 1.5% float · 1.4d Short vol32% Last earningsMay 12, 2026 DataFeb 2024–Jul 2026 Filing10-Q · May 12
Up next
Next earnings call
Jul 17, 2026 Est · unconfirmed · this week
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 12, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Equibles Rating blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Neutral Momentum Very Weak Sentiment Bullish Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 16.5 · calm Equity put/call 0.62
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg −26%
      below
      Price vs 50-day avg +0%
      above
      RSI (14) 52
      neutral
      MACD trend Negative
      52-week position 20%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Weak
      1-month return −6%
      trailing
      6-month return −58%
      trailing
      YTD return −64%
      this year
      Relative strength −69%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $1 › 200d $1 — 200d above 50d
      Institutional flow Accumulating
      1 of 84 funds reported for Jun 30 · net +29.9K sh shares
      Insider flow Accumulating
      Net +$127.4K over 90 days · 0% sells
      Short interest Falling
      1.46% of float · ▼ -0.5% MoM · 1.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      84 holders — mid 2-yr range
      Squeeze score 57
      elevated · 0–100
      Fundamentals
      Weak
      Revenue growth −100%
      Y/Y
      EPS growth −15%
      Y/Y
      Free cash flow $-90.9M
      Balance sheet $81.5M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 122%
      annualized · 1-yr
      Max drawdown −83%
      past year
      ATR 7.7%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Neutral
      2 · 4 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −26% Bearish
      Price vs 50-day avg
      +0% Bullish
      RSI (14)
      52 Neutral
      MACD trend
      Negative Bearish
      52-week position
      20% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $1 › 200d $1 — 200d above 50d
      Institutional flow Accumulating
      1 of 84 funds reported for Jun 30 · net +29.9K sh shares
      Insider flow Accumulating
      Net +$127.4K over 90 days · 0% sells
      Short interest Falling
      1.46% of float · ▼ -0.5% MoM · 1.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      84 holders — mid 2-yr range
      Price context
      position in its 52-week range
      52-wk low $0 Now $1 · 20% 52-wk high $2
      vs 200-day avg -26% vs 50-day avg +0%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      pivotal study participants 300 Q1 FY2026 call —
      pivotal study sites 30 Q1 FY2026 call —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      GUTS
      Fractyl Health, Inc.
      this stock
      		$144.37M -63.6% -100.0% — 1.5%
      ONC
      BeOne Medicines Ltd.
      		 $449.85B +0.9% +22179.2% 915.5 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $121.09B +5.1% +46.2% 28.3 1.9%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $69.66B -14.9% +20.8% 16.2 3.3%
      ARGX
      Argenx SE
      		 $53.96B +2.2% — — 2.3%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      84
      % held
      46.3%
      Reported
      1 of 84
      Top holder
      Nantahala Capital Managem…
      Held Float
      View
      Held by Funds
      Fund positions
      15
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      2.3M
      Days to cover
      1.4d
      Change
      -10.5K sh
      View
      Short Volume
      Short vol %
      32%
      As of
      Jul 15, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      2
      Value
      $1
      As of
      Jun 29, 2026
      View
      Off-Exchange
      Off-exchange %
      73.9%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Cluster buy
      Net (90d)
      +$127.4K
      Buyers / Sellers
      5 / 0
      Buyers Sellers
      View
      Financials
      Financials
      Net income (FY)
      $-141.0M
      EPS diluted
      $-1.86
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 15, 2026
      This year
      16
      View
      Proposed Sales
      Value
      $226.1K
      Shares
      111.9K
      Filed
      Jan 30, 2025
      View
      Exempt Offerings
      Offering
      $20.1M
      Filed
      Jan 25, 2022
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 12, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      GUTS +0.5% -5.9% -58.1% +0.8% -63.6%
      SPY +0.6% +1.4% +11.0% +0.7% +10.3%
      vs SPY -0.1% -7.2% -69.1% +0.1% -73.9%
      Key facts CIK 1572616 CUSIP 35168W103 13F (30d) 1 filings 1 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)